Trade-Ideas LLC identified

Teva Pharmaceutical Industries

(

TEVA

) as a pre-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified Teva Pharmaceutical Industries as such a stock due to the following factors:

  • TEVA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $263.0 million.
  • TEVA traded 103,762 shares today in the pre-market hours as of 7:39 AM.
  • TEVA is down 2% today from yesterday's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in TEVA with the Ticky from Trade-Ideas. See the FREE profile for TEVA NOW at Trade-Ideas

More details on TEVA:

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The stock currently has a dividend yield of 2.2%. TEVA has a PE ratio of 29. Currently there are 14 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 4 rate it a hold.

The average volume for Teva Pharmaceutical Industries has been 6.6 million shares per day over the past 30 days. Teva has a market cap of $47.1 billion and is part of the health care sector and drugs industry. Shares are down 21.4% year-to-date as of the close of trading on Thursday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Teva Pharmaceutical Industries as a

buy

. The company's strengths can be seen in multiple areas, such as its increase in net income, attractive valuation levels, expanding profit margins, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.

Highlights from the ratings report include:

  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Pharmaceuticals industry. The net income increased by 42.6% when compared to the same quarter one year prior, rising from $446.00 million to $636.00 million.
  • The gross profit margin for TEVA PHARMACEUTICALS is rather high; currently it is at 63.97%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 13.22% trails the industry average.
  • The current debt-to-equity ratio, 0.34, is low and is below the industry average, implying that there has been successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.86 is somewhat weak and could be cause for future problems.
  • TEVA PHARMACEUTICALS has improved earnings per share by 19.2% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, TEVA PHARMACEUTICALS reported lower earnings of $1.82 versus $3.56 in the prior year. This year, the market expects an improvement in earnings ($5.21 versus $1.82).

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.